Acquisitions, NDA Filings, Key Findings, Conferences and Product Launches - Research Report on Perrigo, Forest Labs, Avanir

 Acquisitions, NDA Filings, Key Findings, Conferences and Product Launches -
   Research Report on Perrigo, Forest Labs, Avanir Pharmaceuticals, Cubist
                Pharmaceuticals, and Dr. Reddy's Laboratories

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, September 2, 2013

NEW YORK, September 2, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Perrigo
Co. (NYSE: PRGO), Forest Laboratories Inc. (NYSE: FRX), Avanir Pharmaceuticals
(NASDAQ: AVNR), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), and Dr. Reddy's
Laboratories Ltd. (NYSE: RDY). Today's readers may access these reports free
of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Perrigo Co. Research Report

On August 28, 2013, Perrigo Co. (Perrigo), along with Elan Corporation, plc.
(Elan), announced that Perrigo Company Limited (New Perrigo) successfully
filed a registration statement on Form S-4 in connection with Perrigo's
proposed acquisition of Elan, which included a joint proxy statement of Elan
and Perrigo (the Form S-4). Formerly announced on July 29, 2013, Perrigo and
Elan signed a definitive agreement, under which New Perrigo will procure Elan
in a stock-and-cash transaction valued at an estimated $8.6 billion (the
Acquisition). The Full Research Report on Perrigo Co. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/4168_PRGO]

--

Forest Laboratories Inc. Research Report

On August 14, 2013 Forest Laboratories Inc. (Forest Labs) and Almirall, S.A.
(Almirall) announced that they will defer the planned Q4 2013 submission of a
New Drug Application (NDA) for the combination of aclidinium bromide, a long
acting muscarinic antagonist and formoterol fumarate, a long acting beta
agonist, for the purpose of indicating Chronic Obstructive Pulmonary Disease
(COPD). The Company stated that the decision was made due to comments from the
FDA at a recent pre-NDA meeting. According to Forest Labs, the delay related
to resolving chemistry, manufacturing and control (CMC) specifications
associated with the combination formulation. Forest Labs and Almirall are
working with the FDA to address the CMC related comments given at the pre-NDA
meeting to determine the future course of action, and it expects to provide an
update when more data is available. Further, the Company said that this
deferment decision does not affect the Tudorza (aclidinium bromide)
monotherapy product. The Full Research Report on Forest Laboratories Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/ea24_FRX]

--

Avanir Pharmaceuticals Research Report

On August 22, 2013, Avanir Pharmaceuticals (Avanir) announced the publication
of the findings from the PRISM patient registry in PLOS ONE, an international,
peer-reviewed, open-access medical journal. PRISM was the largest registry
ever conducted to deeply understand the prevalence and impact of pseudobulbar
affect (PBA) in the United States. Randall Kaye, MD, Chief Medical Officer at
Avanir commented, "The results from PRISM demonstrate that PBA symptoms are
common among patients with diverse neurological conditions R. Higher CNS-LS
scores were associated with significantly worse quality of life scores and
greater use of antipsychotic/antidepressant medications. Publication of this
important information will help healthcare practitioners better appreciate the
frequency and multi-faceted impact of PBA symptoms in their neurologic
patients." The Full Research Report on Avanir Pharmaceuticals - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/2ee8_AVNR]

--

Cubist Pharmaceuticals Inc. Research Report

On August 28, 2013, Cubist Pharmaceuticals Inc. (Cubist) announced that its
CEO, Mike Bonney, will present at the Morgan Stanley Global Healthcare
Conference, where he will review the Company's business activities, financial
outlook, and current news. Cubist further informed that the event will take
place at the Grand Hyatt New York hotel in New York City on September 9, 2013
at 3:50 p.m. ET. An audio-only presentation will be available via the Company
website through the Investor Relations Conference Calendar section, and will
be available for at least 30 days after the presentations. The Full Research
Report on Cubist Pharmaceuticals Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.AnalystsCorner.com/r/full_research_report/92f2_CBST]

--

Dr. Reddy's Laboratories Ltd. Research Report

On August 22, 2013, Dr. Reddy's Laboratories Ltd. (Dr. Reddy's) announced that
it has successfully launched Divalproex Sodium Extended - Release Tablets, USP
(250 mg and 500 mg), a therapeutic equivalent of the generic version of
Depakote ER (divalproex sodium) Tablet, Extended Release in the US market on
August 19, 2013. The Company informed that the United States Food & Drug
Administration (USFDA) approved Dr. Reddy's ANDA for Divalproex Sodium
Extended- Release Tablets, USP. Further, according to an IMS Heath report, the
Depakote ER brand and generic had combined U.S. sales of approximately $194
million MAT for the most recent twelve months ending in June 2013. The Full
Research Report on Dr. Reddy's Laboratories Ltd. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.AnalystsCorner.com/r/full_research_report/ea85_RDY]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.